June 2019 - Volume 3 - Issue - Contributor Index

Author:
Xafaki, P.
Author:
Xagoraris, I.

COMPARISON OF RITUXIMAB DOSE-ADJUSTED EPOCH (R-DA-EPOCH) WITH RITUXIMAB-CHOP (R-CHOP) CHEMOTHERAPY IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): PF297

Vassilakopoulos, T.; Mellios, Z.; Verigou, E.; More

HemaSphere. 3:100-101, June 2019.

PET-SCAN FOR RESPONSE ASSESSEMENT AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): CLINICAL AND PROGNOSTIC SIGNIFICANCE: PS1089

Vassilakopoulos, T.; Chatzidimitriou, C.; Mellios, Z.; More

HemaSphere. 3:494, June 2019.

Author:
Xaus, J.
Author:
Xavier, L.
Author:
Xenocostas, A.

DOUBLING TIME AFTER FIRST ATTEMPT OF IMATINIB DISCONTINUATION IS HELPFUL TO IDENTIFY THE BEST CANDIDATE FOR THE SECOND ATTEMPT FOR TREATMENT-FREE REMISSION WITH DASATINIB: CANADIAN TRAD TRIAL: PF410

Kim, D.; Busque, L.; Forrest, D.; More

HemaSphere. 3:157-158, June 2019.

Author:
Xia, J.
Author:
Xia, J. T.
Author:
Xia, L.
Author:
Xia, Q.
Author:
Xia, Z.
Author:
Xiang, X.
Author:
Xiao, X.
Author:
Xiao, Z.
Author:
Xicoy, B.
Author:
Xie, B.
Author:
Xie, X.
Author:
Ximeri, M.

CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): CLINICAL SIGNIFICANCE OF ABSOLUTE CLONAL B CELL COUNTS: PS1258

Kalpadakis, C.; Pangalis, G.; Konstantinou, I.; More

HemaSphere. 3:575, June 2019.

EVALUATION OF THE QUANTITATIVE CHARACTERISTICS OF MYELOID DERIVED SUPPRESSOR CELLS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND ASSOCIATED HYPOGAMMAGLOBULINEMIA: PB1881

Zavisanou, K.; Bizymi, N.; Ioneskou, K.; More

HemaSphere. 3:857, June 2019.

Author:
Xing, G.
Author:
Xing, H.
Author:
Xiong, M.
Author:
Xiong, W.
Author:
Xu, E.
Author:
Xu, H.
Author:
Xu, J.
Author:
Xu, L.
Author:
Xu, L.-P.

INCIDENCE, RISK FACTORS AND OUTCOMES OF SINUSOIDAL OBSTRUCTION SYNDROME AFTER HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION: PB2361

Cai, X.; Wu, J.; Gui, R.-Y.; More

HemaSphere. 3:1052, June 2019.

Author:
Xu, M.
Author:
Xu, Q.

FT-2102, AN IDH1 M INHIBITOR, INDUCES MUTATION CLEARANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) TREATED IN PHASE 1 DOSE ESCALATION AND EXPANSION STUDY: PS1051

De Botton, S.; Watts, J.; Baer, M.; More

HemaSphere. 3:475-476, June 2019.

Author:
Xu, W.

TARGETING WILMS TUMOR 1 WITH A T CELL BISPECIFIC ANTIBODY (WT1-TCB): EX VIVO AND IN VIVO POTENCY BY BIVALENT RECOGNITION OF PEPTIDE-MHC COMPLEXES FROM AN INTRACELLULAR TUMOR ANTIGEN: PF207

Augsberger, C.; Klein, C.; Heitmüller, C.; More

HemaSphere. 3:56, June 2019.

Author:
Xu, X.
Author:
Xu, Y.
Author:
Xue, K.
Show: